Literature DB >> 27534579

How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Giulio Metro1, Guido Bellezza2, Francesco Puma3, Rita Chiari1.   

Abstract

Entities:  

Keywords:  ALK; ALK-TKI; Alectinib; central nervous system metastases; ceritinib; crizotinib; lorlatinib; non-small cell lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27534579     DOI: 10.1080/14737140.2016.1226138

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  1 in total

1.  Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

Authors:  Biagio Ricciuti; Giuseppe Lamberti; Fausto Roila; Giulio Metro
Journal:  Transl Lung Cancer Res       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.